perbb3 antibody (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
90
Structured Review
Cell Signaling Technology Inc
perbb3 antibody
Perbb3 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/perbb3/anti+perbb3+y1289/pmc09770245__biolopen___11___059623___s1-40-5-6
Average 90 stars, based on 1 article reviews
Perbb3 Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/perbb3/anti+perbb3+y1289/pmc09770245__biolopen___11___059623___s1-40-5-6
Average 90 stars, based on 1 article reviews
perbb3 antibody - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Incubation:Article Title: Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Article Snippet: 1 Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1–mediated lung cancer Dong Hoon Shin1, 2*, Jeong Yeon Jo1, 2, Ji-Youn Han1* 1Research institute, 2Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea *These authors contributed equally to this study Corresponding Author: Dong Hoon Shin, Ph.D. Translational Research Branch, Research Institute, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea.. Tel: +82-31-920-2488, E-mail: dhshin@ncc.re.kr Corresponding Author: Ji-Youn Han, M.D., Ph.D.. Precision Medicine Branch, Research Institute and Hospital, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea. Blocking Assay:Article Title: Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1-Mediated Lung Cancer. Article Snippet: 1 Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1–mediated lung cancer Dong Hoon Shin1, 2*, Jeong Yeon Jo1, 2, Ji-Youn Han1* 1Research institute, 2Cancer Biomedical Science, Graduate School of Cancer Science and Policy, National Cancer Center, Goyang-si, Gyeonggi-do, Republic of Korea *These authors contributed equally to this study Corresponding Author: Dong Hoon Shin, Ph.D. Translational Research Branch, Research Institute, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea.. Tel: +82-31-920-2488, E-mail: dhshin@ncc.re.kr Corresponding Author: Ji-Youn Han, M.D., Ph.D.. Precision Medicine Branch, Research Institute and Hospital, National Cancer Center, 111 Jungbalsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 410-769, Korea. |